{
    "clinical_study": {
        "@rank": "51997", 
        "arm_group": [
            {
                "arm_group_label": "Brimonidine Tartrate", 
                "arm_group_type": "Experimental", 
                "description": "Brimonidine tartrate ophthalmic solution 0.025%, one drop of drug into each eye, four times daily for up to 30 days."
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle of brimonidine tartrate ophthalmic solution, one drop of vehicle into each eye, four times daily for up to 30 days."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% with\n      its vehicle for treating ocular redness in a population of adult and geriatric participants\n      with ocular redness."
        }, 
        "brief_title": "Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects With Ocular Redness.", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperemia", 
        "condition_browse": {
            "mesh_term": "Hyperemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age.\n\n          -  Have a history of redness relief drops use, or expressed a desire to use drops for\n             redness relief, within the last 6 months.\n\n          -  Have ocular health within normal limits including a calculated best-corrected visual\n             acuity of 0.3 logMAR or better in each eye, as measured using an ETDRS chart.\n\n        Exclusion Criteria:\n\n          -  Any ocular/systemic health problems.\n\n          -  Use of any disallowed medications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959230", 
            "org_study_id": "861"
        }, 
        "intervention": [
            {
                "arm_group_label": "Brimonidine Tartrate", 
                "intervention_name": "Brimonidine Tartrate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Brimonidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Ocular redness", 
        "lastchanged_date": "November 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07940"
                }, 
                "name": "Bausch & Lomb Incorporated"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Adult and Geriatric Subjects With Ocular Redness", 
        "overall_contact": {
            "email": "kris.hartman@bausch.com", 
            "last_name": "Kris Hartman", 
            "phone": "585-338-5165"
        }, 
        "overall_official": {
            "affiliation": "Bausch & Lomb Incorporated", 
            "last_name": "Quintus Ngumah, OD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Ocular redness evaluated by the investigator prior to investigational drug instillation and up to 240 minutes post investigational drug instillation (0-4 unit scale, allowing half unit increments) at Visit 1.", 
            "measure": "Ocular Redness - Investigator", 
            "safety_issue": "No", 
            "time_frame": "240 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959230"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Ocular redness evaluated by the participant as captured in participants' diaries (0-4 unit scale, NOT allowing half unit increments).", 
                "measure": "Ocular Redness - Participant", 
                "safety_issue": "No", 
                "time_frame": "5 Weeks"
            }, 
            {
                "description": "Ocular redness evaluated by the investigator prior to investigational drug instillation and at up to 480 minutes post investigational drug instillation at Visit 1; 5 minutes post investigational drug instillation at Visits 2 and 3.(0-4 unit scale, allowing half unit increments)", 
                "measure": "Ocular Redness - Investigator", 
                "safety_issue": "No", 
                "time_frame": "Visit 1 (Day 1) and Visit 2 (Day 15) and Visit 3 (Day 29)"
            }
        ], 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "collaborator": {
                "agency": "ORA, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}